Literature DB >> 21417847

PLX4032 and melanoma: resistance, expectations and uncertainty.

Dimitrios H Roukos.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21417847     DOI: 10.1586/era.11.3

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  7 in total

Review 1.  New vitamin D analogs as potential therapeutics in melanoma.

Authors:  Paulina Szyszka; Michal A Zmijewski; Andrzej T Slominski
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

2.  Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis.

Authors:  Zhao Wang; Jianjun Chen; Jin Wang; Sunjoo Ahn; Chien-Ming Li; Yan Lu; Vivian S Loveless; James T Dalton; Duane D Miller; Wei Li
Journal:  Pharm Res       Date:  2012-03-13       Impact factor: 4.200

3.  miR-495 inhibits proliferation, migration, and invasion and induces apoptosis via inhibiting PBX3 in melanoma cells.

Authors:  Guangxiong Chen; Yijie Xie
Journal:  Onco Targets Ther       Date:  2018-04-05       Impact factor: 4.147

4.  MicroRNA-26a inhibits the growth and invasiveness of malignant melanoma and directly targets on MITF gene.

Authors:  Hui Qian; Chen Yang; Yixin Yang
Journal:  Cell Death Discov       Date:  2017-07-10

5.  lncRNA-ATB functions as a competing endogenous RNA to promote YAP1 by sponging miR-590-5p in malignant melanoma.

Authors:  Kuanhou Mou; Bo Liu; Meiling Ding; Xin Mu; Dan Han; Yan Zhou; Li-Juan Wang
Journal:  Int J Oncol       Date:  2018-06-25       Impact factor: 5.650

6.  Circ_0084043 promotes cell proliferation and glycolysis but blocks cell apoptosis in melanoma via circ_0084043-miR-31-KLF3 axis.

Authors:  Songjiang Wu; Yuhan Tang; Wenli Liu
Journal:  Open Life Sci       Date:  2020-10-22       Impact factor: 0.938

7.  miR‑590‑5p inhibits tumor growth in malignant melanoma by suppressing YAP1 expression.

Authors:  Kuanhou Mou; Meiling Ding; Dan Han; Yan Zhou; Xin Mu; Wenli Liu; Lijuan Wang
Journal:  Oncol Rep       Date:  2018-08-07       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.